• Arcutis Biotherapeutics EVP, Chief Legal Officer Masaru Matsuda reported sales of 8,256 common shares on May 4, 2026.
• Sales priced at USD 23.27 per share for 7,372 shares, USD 23.61 per share for 884 shares.
• Beneficial ownership stood at 126,689 common shares following transactions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcutis Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001798679-26-000002), on May 06, 2026, and is solely responsible for the information contained therein.